AR025562A2 - Compuestos l-nucleosidos de purina - Google Patents
Compuestos l-nucleosidos de purinaInfo
- Publication number
- AR025562A2 AR025562A2 ARP000104639A AR025562A2 AR 025562 A2 AR025562 A2 AR 025562A2 AR P000104639 A ARP000104639 A AR P000104639A AR 025562 A2 AR025562 A2 AR 025562A2
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- lymphocytes
- cytokines
- assistant
- cell
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 7
- 102000004127 Cytokines Human genes 0.000 abstract 4
- 108090000695 Cytokines Proteins 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 4
- 210000004698 lymphocyte Anatomy 0.000 abstract 4
- 230000024932 T cell mediated immunity Effects 0.000 abstract 3
- 230000004044 response Effects 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000007246 mechanism Effects 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 102000003814 Interleukin-10 Human genes 0.000 abstract 1
- 108090000174 Interleukin-10 Proteins 0.000 abstract 1
- 102000003816 Interleukin-13 Human genes 0.000 abstract 1
- 108090000176 Interleukin-13 Proteins 0.000 abstract 1
- 102000004388 Interleukin-4 Human genes 0.000 abstract 1
- 102000000743 Interleukin-5 Human genes 0.000 abstract 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 102000000585 Interleukin-9 Human genes 0.000 abstract 1
- 102000008072 Lymphokines Human genes 0.000 abstract 1
- 108010074338 Lymphokines Proteins 0.000 abstract 1
- 210000000447 Th1 cell Anatomy 0.000 abstract 1
- 210000004241 Th2 cell Anatomy 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000004727 humoral immunity Effects 0.000 abstract 1
- 230000008348 humoral response Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 229960003130 interferon gamma Drugs 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 230000001151 other effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 210000001541 thymus gland Anatomy 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Los sistemas inmunologicos de los mamíferos contienen dos clases principales de linfocitos: los linfocitos B (células B) que se originan en la médula osea,y los linfocitos T (células T) que se originan en el timo. Las células B son responsables en una gran medida de la inmunidad humoral (es decir, la produccionde anticuerpos) mientras que las células T son responsables en gran medida de la inmunidad mediada por células. En general se considera que las células T sedividen en dos subclases: células T asistentes y células T citotoxicas. Las células T asistentes activan otros linfocitos, incluso las células B y las célulasT citotoxicas, y macrofagos, a través de la liberacion de mediadores de proteínas solubles llamados citoquinas que están implicados en la inmunidad mediada porcélulas. Conforme a la presente, las linfoquinas son una subclase de citoquinas. También se considera que las células T asistentes en general se dividen en dossubclases: Th1 y Th2. Las células Th1 (también conocidascomo células Tipo 1) producen interleuquina 2 (IL-2) factor de necrosis tumoral (TNF alfa) einterferon gamma (IFN gamma), y son responsables fundamentalmente de la inmunidad mediada por células como por ejemplo la hipersensibilidad de tipo demoradoyla inmunidad antiviral. Por el contrario, las células Th2 (también conocidas como células Tipo 2) producen las interleuquinas IL4, IL5, IL6, IL9, IL10 e IL13,y están implicadas fundamentalmente en la asistencia a las respuestas inmuno humorales comolas que se observan en respuesta a los alergenos, por ejemplo, elcambio de isotipo de anticuerpos IgE e IgG1. Las respuestas de Th1 y Th2 comprenden el rango completo de efectos que resultan de la induccion de los linfocitosTh1 y Th2, respectivamente. Entre otras cosas, tales respuestas comprenden la variacion en la produccion de las correspondientes citoquinas por transcripcion,traduccion, secrecion y posiblemente otros mecanismos, la mayor proliferacion de los correspondientes linfocitos, y otros efectos asociados con la mayorproduccion de citoquinas, incluso los efectos de movilidad. Los mecanismos a través de los cuales los nucleosidos y otros compuestos modulan selectivamente las
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP000104639 AR025562A2 (es) | 2000-09-05 | 2000-09-05 | Compuestos l-nucleosidos de purina |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP000104639 AR025562A2 (es) | 2000-09-05 | 2000-09-05 | Compuestos l-nucleosidos de purina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025562A2 true AR025562A2 (es) | 2002-12-04 |
Family
ID=45570904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104639 AR025562A2 (es) | 2000-09-05 | 2000-09-05 | Compuestos l-nucleosidos de purina |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR025562A2 (es) |
-
2000
- 2000-09-05 AR ARP000104639 patent/AR025562A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luger et al. | IFN-beta 2/IL-6 augments the activity of human natural killer cells. | |
| Horii et al. | Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. | |
| Goldman et al. | Cytokines in human milk: properties and potential effects upon the mammary gland and the neonate | |
| Kirnbauer et al. | IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. | |
| Salami et al. | Immunomodulatory effects of mesenchymal stem cells on leukocytes with emphasis on neutrophils | |
| Paradowska et al. | Constitutive and induced cytokine production by human placenta and amniotic membrane at term | |
| Atzpodien et al. | Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms | |
| Shen et al. | Influence of elevated temperature on natural killer cell activity, lymphokine-activated killer cell activity and lectin-dependent cytotoxicity of human umbilical cord blood and adult blood cells | |
| Thornton et al. | Interaction of immune and connective tissue cells: I. The effect of lymphokines and monokines on fibroblast growth | |
| Abb et al. | Age-related decline of human interferon alpha and interferon gamma production | |
| Malkovský et al. | The interleukins in acquired disease | |
| Sato et al. | Recombinant human interleukin 1 alpha and beta stimulate mouse osteoblast-like cells (MC3T3-E1) to produce macrophage-colony stimulating activity and prostaglandin E2 | |
| AR025562A2 (es) | Compuestos l-nucleosidos de purina | |
| Limb et al. | Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2 | |
| Herbelin et al. | IL-7 is requisite for IL-1-induced thymocyte proliferation. Involvement of IL-7 in the synergistic effects of granulocyte-macrophage colony-stimulating factor or tumor necrosis factor with IL-1 | |
| Luttmann et al. | Modulation of cytokine release from mononuclear cells by prostacyclin, IL-4 and IL-13 | |
| Dubois et al. | Synergistic cytotoxic effects of recombinant human tumor necrosis factor, interferons, and heat-stress | |
| Tao et al. | In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia | |
| Platter et al. | Lymphokines and monokines in the clinic | |
| Arenzana-Seisdedos et al. | Immunoregulatory mediators in the pathogenesis of rheumatoid arthritis | |
| Takeuchi et al. | Comparative analysis of interleukin 15 and interleukin 2 for induction of killer activity and of type 2 cytokine production by mononuclear cells from lung cancer patients | |
| Lakshmi Rao et al. | Administration of anti‐IL‐12 antibody in vivo inhibits rejection of a rat histiocytoma and suppresses cytokine response in a tumour‐bearing host | |
| Kim | The cytokines: an overview | |
| Torcia et al. | Biologic and clinical significance of cytokine production in B‐cell malignancies | |
| Attallah et al. | Biological response modifiers and their promise in clinical medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |